2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Gene Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1144 Targeting annexin A1 to prevent hemolysis-driven cerebral vasculopathy in sickle cell disease

Adekunle Emmanuel Alagbe, MD, PhD, Natalie Kim2, Elle Michaud3, Shane C Lenhart, BS4, Qiyang Chen, PhD5, Lynda Little-Ihrig6, Maureen Mburu, MD7, Xucai Chen, PhD8, Enrico M Novelli, MD9, Samit Ghosh, PhD10, Sruti Shiva, PhD11, Kang Kim, PhD12, Flordeliza Villanueva, MD13, Rimi Hazra, PhD14
1 Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
2 Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
3 Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
4 Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
5 Division of Cardiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
6 Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
7 Division of Cardiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
8 Division of Cardiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
9 Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States, University of Maryland, Baltimore, Maryland, United States
10 Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
11 Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
12 Division of Cardiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, United States, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
13 Division of Cardiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
14 Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Cerebral vasculopathy contributes to white matter injury, neuroaxonal damage, and cognitive impairment in sickle cell disease (SCD). Intravascular hemolysis releases extracellular heme, which activates cerebral endothelium, disrupts endothelial-astrocyte coupling, and promotes neurovascular injury. We recently showed that heme challenge in Townes sickle mice exacerbates microstructural white matter damage, including reduced fractional anisotropy, increased SMI32/MBP ratio, and astrocyte reactivity. Neutrophilic ANXA1, a pro-resolving factor, is recognized for its ability to resolve thrombo-inflammatory cerebral vasculopathy in SCD. However, whether full-length recombinant ANXA1 (rANXA1) directly protects the cerebral neurovascular unit from hemolysis-driven injury remains unknown. We hypothesized that acute hemolytic stress suppresses ANXA1 signaling in the cerebral endothelium and microglia, promoting neuroinflammation and white matter vulnerability, whereas rANXA1 restores neurovascular homeostasis.

Adult Townes sickle mice (10-12 weeks old) expressing human sickle hemoglobin (SS) and control mice expressing human HbA (AA) were injected intravenously with ferric heme (20 µmoles/kg) or vehicle. A subset of SS mice received rANXA1 (50 mg/kg i.v.) before heme challenge. Brains were harvested 24 hours later and analyzed by immunofluorescence for neuroaxonal damage and neuronal apoptosis using SMI32/MBP and NeuN/TUNEL co-staining respectively. We assessed neuroinflammation marker S100B and ANXA1 expression in IBA1+ microglia, and CD31+ cerebral endothelium. To establish a translational imaging framework, the CD31-defined cerebrovascular distribution was compared with super-resolution ultrasound (SRU), a novel non-invasive imaging method for visualizing the microcirculation in vivo, to quantify perfused microvascular density and flow velocity in AA and SS mice.

Heme challenge produced marked neurovascular injury in SS mice. Cortical NeuN+/TUNEL+ apoptotic neurons increased 3.5-fold in heme-challenged SS mice (n=5-9; p<0.0001), accompanied by ~2-fold increase in S100B expression (p<0.0001), suggesting neuronal stress and neuroinflammation. Heme also reduced endogenous ANXA1 signaling in CD31+ endothelium (ANXA1/CD31; n=6; p<0.05). Compared with vehicle, rANXA1 pretreatment maintained ANXA1 expression in IBA1+ microglia (n=5; p<0.0001) and CD31+ endothelial cells (n=5; p=0.037). rANXA1 provided broad neurovascular protection after heme challenge. In vehicle-treated SS mice, rANXA1 prophylaxis significantly improved neuronal apoptosis (p=0.002), S100B expression (p=0.0042), and reduced white matter injury in the corpus callosum/external capsule (p<0.01). In a parallel study, SRU demonstrated region-specific cerebral microvascular remodeling in SS mice, including increased cortical flow velocity with relatively higher cortical vessel density, but reduced vessel density in hippocampus (n=5-6; p<0.05) and internal brain (n=5-6; p=0.011). Concordantly, CD31 immunofluorescence showed higher cortical CD31+ vessel density in SS mice (n=5; p<0.0001), but lower CD31+ vessel density in external capsule/corpus callosum (p=0.043), hippocampus (p=0.003), and internal brain (p<0.0001). In summary, this proof-of-concept study identifies ANXA1-dependent neurovascular protection as a potential mechanism to counter hemolytic cerebrovascular injury in SS mice. These findings substantiate rANXA1 as a therapeutic strategy for cerebral vasculopathy and suggest SRU-guided longitudinal imaging as a translational approach to monitor neurovascular protection in SCD. Future studies will assess the longevity of rANXA1-mediated neurovascular protection and validate SRU as an imaging biomarker of cerebral vasculopathy in SCD.

Adekunle Emmanuel Alagbe, MD, PhD: No relevant conflicts of interest to declare.